Kura Oncology, Inc.
Methods and compositions for inhibiting the interaction of menin with MLL proteins

Last updated:

Abstract:

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

Status:
Grant
Type:

Utility

Filling date:

3 Jun 2016

Issue date:

17 Mar 2020